Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye
Recruiting now · Phase 4
Conditions studied: Juvenile Open Angle Glaucoma, Dry Eye Disease (DED), Interleukin 6, Retinal Nerve Fiber Layer Thickness, HbA1c Level
In brief
The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.
Key facts
- Study ID
- NCT07396441
- Run by
- Universiti Sains Malaysia
- People needed
- 60
- Starts
- 2026-01-15
- Expected to finish
- 2026-06-30
- Last updated by the study team
- 2026-02-09
Who can join
Age: 15 and older, up to 40. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- JOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure
You may not qualify if…
- Patients with allergy to honey or honey-based products OCT signal less than 6/10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.
- Sepsis Compliance less than 75%.
Where it is running
- Hospital Raja Perempuan Zainab II — Kota Bharu, Kelantan, Malaysia (enrolling)
- Hospital Sultan Ismail Petra — Kuala Krai, Kelantan, Malaysia (enrolling)
- Hospital Universiti Sains Malaysia — Kubang Kerian, Kelantan, Malaysia (enrolling)
- Hospital Sultanah Nur Zahirah — Kuala Terengganu, Terengganu, Malaysia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.